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Previewsfunction and heart pathologies. Thus,
there is an obvious need to understand
the signals and cues that direct cardio-
myocyte diversity and promote electrical
and mechanical maturation. This goal is
challenging using embryos generated
with conventional transgenic technolo-
gies since many genes have multiple
essential roles and their inactivation early
on can mask later functions. As a result,
PSCs represent a straightforward means
to dissect the molecular basis for late-
stage developmental or maturational
events by bringing in novel technologies
such as siRNAs, miRNAs, or small mole-
cules, especially using high-throughput
technology.
In summary, embryology redux can
lead to efficient, directed differentiation
of PSCs, enhancing knowledge of
embryogenesis and increasing the rele-126 Cell Stem Cell 8, February 4, 2011 ª2011vance of PSC-derived cells for practical
applications and research. This and other
recent examples of efficient differentiation
[e.g., pancreatic endocrine cells and
motor neurons (Kroon et al., 2008; Wich-
terle et al., 2002) bring us one step closer
to being able to scrutinize highly complex
normal and pathological behaviors of
terminally differentiated cells in culture
dishes.REFERENCES
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Individuals carrying deleterious BRCA1 mutations typically develop basal-like rather than luminal breast
cancers. In this issue of Cell Stem Cell, Proia et al. (2011) study breast tissue from women with heterozygous
BRCA1 mutations and identify molecular mechanisms that regulate mammary progenitor cell differentiation
and bias toward subsequent basal-like tumor formation.Since the early 1990s, investigators have
known that certain families contain
women who exhibit a significant
increased lifetime risk for breast and
ovarian cancer. In this population, the
genetic locus responsible for this risk,
BRCA1, is heterozygous for deleterious
mutations where one copy of the gene is
truncated, mutated, deleted, or silenced
by DNA hypermethylation (Ostermeyer
et al., 1994). Breast tumors that form in
these women are unusual on several
levels. First, the tumors develop at an early
age and are a manifestation of an
increased lifetime risk of developing
breast cancer. Although several BRCA1
functions may be altered in individuals
who bear a mutated copy of the gene,the actual molecular basis for this
increased risk is unknown. Second, the
tissue types that exhibit an increased like-
lihood of developing tumors are restricted
to a small number, mostly breast and
ovarian tissues. Why the increased risk
for cancer does not extend to other
organs or lineages is also amystery. Third,
and the topic of this Preview, the type of
breast cancer that is most typically diag-
nosed in BRCA1 mutation carriers is of
a particular subtype, the highly lethal
basal-like subtype. Understanding how
the BRCA1 protein participates in any of
these threemalignant patterns (Venkitara-
man, 2002) would be amajor step forward
in the effort to treat and eventually eradi-
cate the disease. In this issue of CellStemCell, Proia and colleagues in the Ku-
perwasser laboratorymake use of primary
breast tissue samples isolated from
disease-free BRCA1 mutation carriers
(Proia et al., 2011). The authors present
a carefully crafted study that addresses
the origin of the basal-like phenotype
that predominates in the tumors that
develop in these women. This study
constitutes a cornerstone in the field as
the use of tissues obtained from women
that carry these mutations provides
unparalleled opportunities to gain insights
into the molecular events that underlie the
puzzles noted above. Through a compel-
ling set of supporting data, the authors
reveal that the propensity to generate
basal-like tumors in breast tissue that
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derives from a perturbation in breast
epithelial cell differentiation caused by
a defect in BRCA1 function.
The Kuperwasser laboratory has pio-
neered the development of sophisticated
culture tools that bridge the gap between
animal models and human tumor studies
(Proia and Kuperwasser, 2006). In the
spirit of this approach, they introduced
a cocktail of oncogenes into a bulk popu-
lation of human breast epithelial cells
obtained from disease-free women that
were either wild-type (BRCA1+/+) or
heterozygous mutant (BRCA1+/mut) and
injected the manipulated cells into a
murine fat pad that had been cleared of
murine epithelial cells and ‘‘humanized’’
by the transplantation of human stromal
fibroblasts (Proia and Kuperwasser,
2006). This strategy allows the introduced
human epithelial cells to expand in an
environment that supports their growth.
The authors then monitored the charac-
teristics of the resulting human breast
tissues and carefully analyzed the
subtype of tumors that formed in this
elegant in vivo model. While wild-type
cells generated both luminal and basal-
like tumors, BRCA1+/mut cells gave rise
to an overrepresentation of basal-like
tumors. These results provide the first
hint that the bias toward forming
a basal-like tumor resides in the spectrum
of cells present in the breast tissue prior to
disease formation. This observation is
consistent with a ‘‘cell of origin’’ explana-
tion for tumor subtype since the trans-
forming oncogenes introduced in both
wild-type and BRCA1+/mut cells were
identical.
In a complementary approach, an in-
depth examination of the resident cells
present within the patient-derived,
disease-free tissue was performed using
flow cytometry, mammosphere formation
analysis, and in vivo outgrowth assays.
The results of these efforts demonstrated
that luminal progenitors from BRCA1+/mut
tissue exhibit defects in luminal matura-
tion and differentiation and unexpectedly
give rise to basal-like differentiation
phenotypes. It was further demonstrated
that basal-like tumors were derived from
luminal progenitors that underwentincreased basal differentiation. Strikingly,
the authors found that the cell-fate deci-
sion that directed progeny toward either
a luminal or basal outcome is governed
by the activity of the transcription factor
SLUG, which falls under the regulation of
BRCA1. Thus, haploinsufficiency for
BRCA1 protein activity in mutant carriers
results in a lack of turnover of SLUG and
a subsequent bias toward basal differenti-
ation. To state the converse, SLUG
expression regulates human breast
progenitor cell differentiation and blocks
luminal differentiation. This increased
expression of SLUG protein was subse-
quently observed in BRCA1+/mut tissue
prior to disease. Finally, the authors docu-
mented that the expression of SLUG
protein is both necessary and sufficient
for in vitro progenitors to adopt the
basal-like phenotype.
As the authors emphasize, their current
studies identify one way that BRCA1 may
influence tumor subtype but do not
preclude other mechanisms. Indeed, the
identification of specific factors that
contribute to increased breast and
ovarian malignancy has been daunting.
Given that the BRCA1 gene codes for an
extremely large protein with multiple func-
tions and that a wide variety of mutation
sites have been documented throughout
the protein’s different domains, it is
possible that some mutations may influ-
ence tumor subtype via an alternative
mechanism. To date, the BRCA1 protein
has been reported to participate in the
maintenance of genomic integrity, DNA
repair processes, transcriptional regula-
tion, cell-cycle-checkpoint control, and
chromatin remodeling through its E3
ubiquitin ligase activity (Boulton, 2006).
The exciting finding unveiled in this report
is that BRCA1 also participates in cell-fate
decisions executed by breast progenitor
cells. This conclusion extends the impact
of previous published studies that indi-
cated that BRCA1 might function to
regulate mammary epithelial cell morpho-
genesis and differentiation (Furuta et al.,
2005; Liu et al., 2008; Kubista et al.,
2002; Hakem et al., 1998). As mentioned
above, the finding that BRCA1 mutations
promote basal-like tumors in a cell auton-
omous fashion by increasing the pool ofCell Stem Cell 8progenitors that exhibit basal differentia-
tion is consistent with a ‘‘cell of origin’’
explanation for tumor subtype. Thus, in
an interesting twist of biology, at least in
this particular tumor example, the tumor’s
‘‘mutation of origin’’ promotes the forma-
tion of the specific subpopulation that
serves as the ‘‘cell of origin’’ for the
basal-like subtype. It will be interesting
to determine if other tumor examples
also demonstrate such a relationship
between genetic alteration and dictation
of cell fate.
Identifying the basis of basal-like tumor
formation is not simply an academic exer-
cise. The basal-like subtype represents
the most lethal and metastatic subtype
of breast tumors, and insights into the
mechanisms that govern its origins or
phenotypes provide new targets to block
tumor formation in at-risk populations, or
to eradicate existing malignant pheno-
types, including metastatic potential
(Lord and Ashworth, 2008).REFERENCES
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